Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Möhler, Markus [VerfasserIn]   i
 Halama, Niels [VerfasserIn]   i
Titel:Immunotherapy in gastrointestinal cancer
Titelzusatz:Recent results, current studies and future perspectives
Verf.angabe:Markus Moehler, Maike Delic, Katrin Goepfert, Daniela Aust, Heike I. Grabsch, Niels Halama, Bernd Heinrich, Catherine Julie, Florian Lordick, Manfred P. Lutz, Murielle Mauer, Maria Alsina Maqueda, Hansjoerg Schild, Carl C. Schimanski, Anna-Dorothea Wagner, Arnaud Roth, Michel Ducreux
E-Jahr:2016
Jahr:31 March 2016
Umfang:11 S.
Fussnoten:Gesehen am 24.10.2019
Titel Quelle:Enthalten in: European journal of cancer
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1992
Jahr Quelle:2016
Band/Heft Quelle:59(2016), Seite 160-170
ISSN Quelle:1879-0852
Abstract:The new therapeutic approach of using immune checkpoint inhibitors as anticancer agents is a landmark innovation. Early studies suggest that immune checkpoint inhibition might also be effective in patients with gastrointestinal cancer. To improve the efficacy of immunotherapy, different strategies are currently under evaluation. This review summarises the discussion during the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Translational Research Meeting in Mainz in November 2014 and provides an update on the most recent results of immune therapy in gastrointestinal cancers. Knowledge of potential relationships between tumour cells and their microenvironment including the immune system will be essential in gastrointestinal malignancies. In this context, the density of T cell infiltration within colorectal cancer metastases has been associated with response to chemotherapy, and a high expression of programmed cell death ligand 1 (PD-L1) in advanced gastric cancer has been related with poor prognosis. Effective targets might include neo-antigens encoded from genes carrying tumour-specific somatic mutations. Tailored immunotherapy based on such mutations could enable the effective targeting of an individual patient’s tumour with vaccines produced on demand. Other strategies considering checkpoint inhibitors have shown efficacy by targeting cytotoxic T-lymphocyte-associated protein 4 and PD-1 or PD-L1. DNA mismatch repair-deficient tumours appear to be potentially the best candidates for these therapies. Finally, the combination of oncolytic viruses with immunotherapy might boost antitumour activity as well. Further evaluation of these promising immunological therapeutic approaches will require large prospective clinical studies.
DOI:doi:10.1016/j.ejca.2016.02.020
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.ejca.2016.02.020
 Volltext: http://www.sciencedirect.com/science/article/pii/S0959804916001362
 DOI: https://doi.org/10.1016/j.ejca.2016.02.020
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Checkpoint inhibitors
 Gastrointestinal cancer
 Immunotherapy
K10plus-PPN:1679764438
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68445147   QR-Code
zum Seitenanfang